TRDA
Entrada Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$548.23M
P/E Ratio
—
EPS
$-3.47
Beta
-0.15
52W High
$14.36
52W Low
$4.93
50-Day MA
$11.87
200-Day MA
$8.58
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3333.33
PEG Ratio
—
About Entrada Therapeutics Inc
Entrada Therapeutics Inc. (TRDA) is a pioneering biotechnology firm committed to developing transformative therapies for severe diseases with considerable unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, the company targets RNA and protein dysfunctions associated with debilitating conditions such as muscular dystrophies and genetic disorders. With a robust clinical pipeline and an emphasis on scientific rigor, Entrada is strategically positioned to advance therapeutic solutions that seek to enhance patient outcomes, supported by a seasoned leadership team focused on innovation in the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $25.42M |
| Gross Profit (TTM) | $-115.15M |
| EBITDA | $-151.90M |
| Operating Margin | -3103.00% |
| Return on Equity | -39.10% |
| Return on Assets | -21.60% |
| Revenue/Share (TTM) | $0.61 |
| Book Value | $8.50 |
| Price-to-Book | 1.65 |
| Price-to-Sales (TTM) | 21.57 |
| EV/Revenue | 10.18 |
| EV/EBITDA | 1.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -96.50% |
| Shares Outstanding | $38.28M |
| Float | $21.58M |
| % Insiders | 12.72% |
| % Institutions | 76.21% |
Historical Volatility
HV 10-Day
60.31%
HV 20-Day
60.17%
HV 30-Day
68.29%
HV 60-Day
60.95%
HV Rank
77.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($20.50 target)
7
BuyData last updated: 4/9/2026